Skip to content

A prospective randomized controlled trial to evaluate different intervene strategy for severe infant hydronephrosis

A prospective randomized controlled trial to evaluate different intervene strategy for severe infant hydronephrosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053497
Enrollment
Unknown
Registered
2021-11-22
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydronephrosis

Interventions

Severe Hydronephrosis B-Delayed Pyeloplasty Group:nephrostomy-pyeloplsty
Severe Hydronephrosis B - Direct Pyeloplasty Group:Pyeloplasty
Severe Hydronephrosis A - Active Surveillance Group:Active Surveillance Gr
Severe Hydronephrosis A - Direct Pyeloplasty Group:Pyeloplasty

Sponsors

The Seventh Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. Children with hydronephrosis aged = 40%; 2. Those who meet one of the following conditions enter the severe hydronephrosis group: (1) Ultrasound assessment APD >= 35mm; (2) SFU grade is grade IV (thinning of renal parenchyma); (3) The renal function assessed by dynamic renal imaging is less than 40%.

Exclusion criteria

Exclusion criteria: 1. The presence of lower urinary tract obstructive diseases such as posterior urethral valves; 2. Malformed kidneys, such as horseshoe kidney, duplication kidney, ectopic fusion kidney, etc.; 3. Bilateral hydronephrosis; 4. Hydronephrosis caused by factors such as posterior inferior vena cava and ureter; 5. Diseases such as primary vesicoureteral reflux, vesicoureteral junction obstruction, obstructive megaureter, ureteral orifice cyst; 6. Children with severe malformations of other systems; 7. Those who have received interventional treatments such as ostomy or catheter placement in other hospitals when visiting a doctor; 8. Patients with poor compliance or without follow-up conditions.

Design outcomes

Primary

MeasureTime frame
Split Renal Function;renal cortical thickness;serum creatinine;

Secondary

MeasureTime frame
time of drainage;Double J tube indwelling days;

Countries

China

Contacts

Public ContactZhou Huixia

The Seventh Center of PLA General Hospital

huixia99999@163.com+86 15101060299

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026